Pleural Mesothelioma: 4 TNM Stages, 4 FDA-Approved Therapies, $150,000–$1,000,000+ Treatment Costs (2026)

Pleural mesothelioma is an aggressive, asbestos-caused cancer of the lining of the lungs (the pleura). It is staged using the International Association for the Study of Lung Cancer (IASLC) 8th edition tumor–node–metastasis (TNM) system across 4 stages, treated with 4 FDA-approved systemic regimens plus highly selective surgery at multidisciplinary centers, and carries a typical first-year billed cost of $150,000–$1,000,000+. Average mesothelioma civil settlements of $1,000,000–$1,400,000 are the single largest source of funding patients use to cover those costs. Free case evaluations are available 24/7 from Danziger & De Llano at (855) 699-5441.

For full treatment-modality detail, see the dedicated Mesothelioma Treatment Options reference page; this page focuses on the disease entity itself — definition, epidemiology, asbestos causation, diagnosis, staging, and prognosis.

Pleural Mesothelioma Cost Facts (verified 2026-05-13)

Treatment cost row	2026 cost range (United States)	Notes
First-year cost	$150,000–$1,000,000+	Total typical first-year billed cost combining diagnostic workup, surgery (when indicated), immunotherapy or chemotherapy (chemo), supportive care, and follow-up imaging.
Immunotherapy / year	$150,000–$200,000	Annual cost of FDA-approved nivolumab + ipilimumab (Nivo+Ipi), the CheckMate 743 regimen approved March 2022 for unresectable malignant pleural mesothelioma (MPM).
Surgery (P/D)	$30,000–$100,000+	Pleurectomy/decortication (P/D) procedural cost; extrapleural pneumonectomy (EPP) costs are similar or higher.
Chemotherapy course	$10,000–$30,000 per cycle	Standard cisplatin/pemetrexed (Pem+Cis) course; a typical full course is 4–6 cycles, so total course cost is roughly $40,000–$180,000.
Average settlement	$1,000,000–$1,400,000	Average mesothelioma civil lawsuit settlement (Mealey's industry benchmark). Trial verdicts range higher.

Executive Summary

Pleural mesothelioma originates in the mesothelial cells lining the pleural cavity — the thin double-layered membrane between the lungs and the chest wall. It is the most common form of mesothelioma, accounting for the majority of incident cases worldwide. The Global Burden of Disease 2019 analysis estimated 34,511 incident mesothelioma cases globally in 2019 (95% uncertainty interval [UI] 31,199–37,771) and 29,251 deaths, with occupational asbestos exposure contributing 85.2% of disability-adjusted life years (DALYs).

The disease has a single established cause: inhaled amphibole and chrysotile asbestos fibers that lodge in the pleura and trigger malignant transformation after a typical latency of 20–50 years from first exposure. Pleural mesothelioma classifies into 3 histologic subtypes (epithelioid, sarcomatoid, biphasic) that drive prognosis and treatment selection. See Asbestos_Exposure and Veterans_Asbestos_Exposure for the full exposure-history framework.

Diagnosis is built on thoracoscopic pleural biopsy confirmed by immunohistochemistry (IHC) — most importantly BRCA1-associated protein 1 (BAP1) IHC and cyclin-dependent kinase inhibitor 2A (CDKN2A) testing — and staged using the IASLC 8th edition TNM system. CDKN2A loss detected by chromogenic in situ hybridization (CISH) is a validated tool for separating benign from malignant mesothelial proliferations, particularly in challenging epithelioid cases.

First-line treatment in 2026 is dictated by histology: nivolumab + ipilimumab (Nivo+Ipi) is the preferred first-line regimen for non-epithelioid (sarcomatoid + biphasic) disease per CheckMate 743 (median overall survival [OS] 18.1 vs. 14.1 months; hazard ratio [HR] for death 0.74; p = 0.002). Pemetrexed + cisplatin (Pem+Cis) — established by the EMPHACIS Phase III trial in 2003 — remains the chemotherapy backbone for patients who are not immunotherapy candidates.

Key Facts

• Pleural mesothelioma is the most common form of mesothelioma, arising in the mesothelial lining of the pleural cavity (the membrane between the lungs and chest wall).
• 34,511 incident mesothelioma cases globally in 2019 (95% UI 31,199–37,771) per the Global Burden of Disease 2019 systematic analysis; 29,251 deaths; 85.2% of DALYs attributable to occupational asbestos.
• Asbestos exposure is the established cause of pleural mesothelioma — both amphibole (crocidolite, amosite) and chrysotile fibers carry quantitative risk per dose.
• Latency is long. First exposure to clinical diagnosis typically spans 20–50 years; this delay is why incident cases continue to surface decades after U.S. industrial asbestos use peaked.
• 3 histologic subtypes — epithelioid (~50–70% of cases, longest median survival), sarcomatoid (~10–20%, most aggressive), and biphasic / mixed (~20–35%, intermediate).
• Diagnosis requires thoracoscopic pleural biopsy with confirmatory immunohistochemistry; BAP1 IHC and CDKN2A CISH are the most clinically impactful adjuncts for separating malignant mesothelioma from benign reactive mesothelial proliferations.
• Staged using IASLC 8th edition TNM (Stages I–IV); see staging section below.
• 4 FDA-approved systemic options (full detail at Treatment_Options): pemetrexed + cisplatin (2004), nivolumab + ipilimumab (2020), pembrolizumab + pemetrexed + platinum (2024), and tumor treating fields (TTFields) under Humanitarian Device Exemption (HDE) with chemotherapy (2019).
• Surgery is restricted to early-stage epithelioid disease at high-volume centers; sarcomatoid histology is a contraindication to maximal cytoreductive surgery in current National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) 2025 guidance.
• CheckMate 743 established immunotherapy as first-line standard for non-epithelioid disease (median OS 18.1 vs. 14.1 months; HR 0.74).
• Compensation funding — civil settlements averaging $1,000,000–$1,400,000, asbestos trust fund payouts, and Veterans Affairs (VA) disability are the primary mechanisms patients use to cover the $150,000–$1,000,000+ first-year cost. Free legal evaluation: Danziger & De Llano at (855) 699-5441.

What is pleural mesothelioma?

Pleural mesothelioma is a malignancy of the mesothelial cells that line the pleural cavity. The pleura is a thin, two-layered serous membrane: the visceral pleura adheres to the surface of each lung, and the parietal pleura lines the inside of the chest wall, the diaphragm, and the mediastinum. A small volume of pleural fluid between the two layers normally allows the lungs to glide as they expand and recoil during breathing.

When inhaled asbestos fibers reach the pleura — typically by translocation from the lung parenchyma over years or decades — they trigger chronic inflammation, mesothelial cell injury, and progressive accumulation of genetic alterations. The result, after a latency commonly measured in decades, is malignant transformation of the pleural lining into a tumor that grows diffusely along the pleural surface, encases the lung, and frequently produces a large pleural effusion.

Pleural mesothelioma is anatomically distinct from peritoneal mesothelioma (which arises in the lining of the abdominal cavity), pericardial mesothelioma (in the lining around the heart), and tunica vaginalis mesothelioma (around the testis). Pleural mesothelioma is by far the most common, accounting for the large majority of incident cases worldwide.

The 3 histologic subtypes

Histologic subtype is the strongest single prognostic factor in pleural mesothelioma — it consistently outweighs stage, treatment, and patient demographics in multivariate analyses across population registries.

Histologic subtype	Approximate prevalence	Clinical course	First-line treatment implication
Epithelioid	50–70% of cases	Most indolent of the three subtypes; longest median overall survival (OS); best response to chemotherapy and surgery	Pemetrexed + cisplatin (Pem+Cis) chemotherapy or nivolumab + ipilimumab (Nivo+Ipi) immunotherapy; surgery considered in early-stage cases at expert centers
Sarcomatoid	10–20% of cases	Most aggressive subtype; shortest median OS; poor response to chemotherapy	Nivolumab + ipilimumab (Nivo+Ipi) preferred per CheckMate 743 (more pronounced benefit in non-epithelioid disease); surgery contraindicated as a maximal cytoreductive intent
Biphasic (mixed)	20–35% of cases	Intermediate course — contains both epithelioid and sarcomatoid components; outcomes depend on the proportion of each	Nivolumab + ipilimumab (Nivo+Ipi) preferred for non-epithelioid-predominant disease; surgery only in highly selected cases

Subtype prevalence ranges and clinical-course descriptions reflect general consensus across published mesothelioma registries; specific median-survival figures by subtype sit outside the verified-citation pool used for this article and are detailed in Treatment_Options where the underlying trial data are discussed.

What causes pleural mesothelioma?

Asbestos exposure is the established cause of pleural mesothelioma. Both amphibole asbestos (crocidolite, amosite, anthophyllite, tremolite, actinolite) and chrysotile (serpentine) asbestos carry quantitative dose-response risk for mesothelioma in published industrial-cohort meta-analyses. Domestic and household-secondary exposure — for example, family members handling work clothing of an exposed worker — has been shown to elevate mesothelioma risk significantly above background.

Common exposure pathways include:

• Occupational exposure — insulators, shipyard workers, boilermakers, pipefitters, electricians, sheet metal workers, plasterers, asbestos miners and millers, asbestos product manufacturing workers, and many other trades that handled asbestos-containing materials between roughly the 1940s and the 1980s.
• Military and Navy service — Navy ships built before the late 1970s used extensive asbestos insulation; veterans who served in engine rooms, boiler rooms, or shipyards face elevated risk. See veterans asbestos exposure for the full pathway.
• Construction and building trades — asbestos was used in floor tile, ceiling tile, joint compound, gaskets, fireproofing sprays, roofing felt, cement pipe, and many other products. Demolition and renovation work continues to expose tradespeople when these materials are disturbed.
• Firefighting — firefighters face elevated cancer risk, including mesothelioma, from repeated exposure to asbestos and other carcinogens released when older buildings burn or are torn apart during fire suppression operations.
• Household / secondary exposure — a worker carries asbestos fibers home on clothing, hair, and skin; family members are exposed when handling those clothes for laundry or simply living in proximity. Documented to elevate mesothelioma risk in spouses, children, and other household contacts.
• Environmental exposure — communities living near asbestos mines, factories, or natural geologic outcrops of amphibole minerals (e.g., Libby, Montana) carry elevated risk independent of occupational history.

For a fuller exposure-pathway framework with employer-by-employer history, see asbestos exposure overview and the Danziger & De Llano jobsite database.

Latency from first exposure

Pleural mesothelioma has one of the longest latency periods of any solid cancer. The interval from first asbestos exposure to clinical diagnosis is typically 20–50 years, with a median often cited around 40 years across published cohorts. This long latency is the central reason mesothelioma incidence in the United States continues to surface decades after industrial asbestos use peaked in the 1970s — and why patients diagnosed in 2026 commonly trace exposure to work performed in the 1960s, 1970s, or 1980s.

How is pleural mesothelioma diagnosed?

Diagnosis of pleural mesothelioma proceeds in three stages: imaging suggestion → tissue acquisition → histopathologic confirmation with immunohistochemistry. A presumptive diagnosis on cytology of pleural fluid alone is not adequate to commit to definitive treatment; tissue biopsy is required.

Imaging

Initial imaging typically consists of:

• Chest X-ray — often the first study; shows a unilateral pleural effusion in the majority of pleural mesothelioma presentations and may show pleural thickening or a pleural mass.
• Contrast-enhanced computed tomography (CT) of the chest — the standard modality for evaluating pleural disease extent, lymph node involvement, and chest-wall invasion.
• Positron emission tomography / computed tomography (PET/CT) — used to evaluate distant metastatic disease and to identify the most metabolically active site for biopsy.
• Magnetic resonance imaging (MRI) — selectively used to assess chest-wall, diaphragm, or vertebral involvement when surgery is being considered.

Tissue acquisition

The diagnostic standard is video-assisted thoracoscopic surgery (VATS) with direct pleural biopsy under direct visualization, which yields adequate tissue for histology, IHC, and molecular testing. Image-guided percutaneous core needle biopsy is an alternative when thoracoscopy is contraindicated, but yields smaller tissue volumes. Cytology of pleural fluid alone is insufficient for definitive diagnosis in most cases.

Histopathology and immunohistochemistry (IHC)

Definitive diagnosis requires histopathologic confirmation by a pathologist experienced in mesothelial tumors, supported by an IHC panel that distinguishes mesothelioma from metastatic adenocarcinoma (most commonly lung adenocarcinoma) and from benign reactive mesothelial proliferations.

Two diagnostic adjuncts have particular clinical impact:

• BAP1 immunohistochemistry (BAP1 IHC) — loss of nuclear BAP1 staining in mesothelial cells favors a malignant rather than reactive process, with high specificity for malignancy in published validation series. BAP1 IHC is now standard in the workup of any indeterminate mesothelial proliferation.
• CDKN2A chromogenic in situ hybridization (CDKN2A CISH) — homozygous deletion of CDKN2A is highly specific for malignancy in mesothelial proliferations. A 2025 American Journal of Surgical Pathology study by Churg and colleagues validated CDKN2A CISH as a tool for separating benign from malignant mesothelial proliferations.

When BAP1 IHC and CDKN2A CISH are combined, the two assays substantially increase diagnostic confidence in challenging cases — particularly early-stage disease where morphology alone is ambiguous.

How is pleural mesothelioma staged?

Pleural mesothelioma is staged using the International Association for the Study of Lung Cancer (IASLC) 8th edition tumor–node–metastasis (TNM) classification, adopted into the American Joint Committee on Cancer (AJCC) staging manual. The system uses three components:

• T (tumor) — extent of primary tumor in the pleura, lung parenchyma, chest wall, diaphragm, and mediastinum (T1–T4).
• N (nodes) — regional lymph node involvement (N0–N2).
• M (metastasis) — distant metastatic disease (M0 / M1).

These components combine into 4 stage groupings:

Stage	General description	Treatment-planning implication
Stage I	Tumor confined to the ipsilateral parietal pleura, possibly with limited visceral pleural involvement; no lymph node involvement (N0); no distant metastasis (M0)	The principal stage in which cytoreductive surgery is considered (epithelioid histology, multidisciplinary evaluation at a high-volume center)
Stage II	More extensive ipsilateral pleural and lung involvement; N0; M0	Surgical candidacy possible in selected cases; trimodality and immunotherapy approaches under active study
Stage III	Locally advanced disease (chest wall, diaphragm, mediastinal pleura, or pericardium involvement) and/or ipsilateral mediastinal / subcarinal nodal involvement (N1–N2); M0	Systemic therapy primary; surgery only in highly selected cases at expert centers
Stage IV	Distant metastasis (M1) and/or contralateral pleural involvement and/or unresectable extensive locoregional disease	Palliative-intent systemic therapy; supportive care; clinical trial enrollment encouraged

Stage definitions summarize the IASLC 8th edition TNM framework as adopted in NCCN and ASCO guidelines; for the full T/N/M descriptor language, refer to the IASLC staging manual or the AJCC Cancer Staging Manual 8th edition.

For SEER (Surveillance, Epidemiology, and End Results) summary-stage 5-year relative survival data by stage at diagnosis, the most current public-domain reference is the National Cancer Institute (NCI) SEER*Explorer Mesothelioma cancer statistics fact sheet. Stage-specific survival figures evolve as datasets are updated and as the proportion of patients receiving immunotherapy grows; readers should consult the live SEER fact sheet for the most recent cohort.

How is pleural mesothelioma treated?

Pleural mesothelioma treatment in 2026 is built around 4 FDA-approved systemic options, with surgery reserved for a narrow subgroup of early-stage epithelioid patients evaluated at high-volume centers. The full treatment-modality reference — including trial data, surgical comparison (P/D vs. EPP), peritoneal cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC), and the 10+ active investigational trials — is at Treatment_Options. This section summarizes the pleural-specific treatment frame.

First-line systemic therapy in 2026

First-line treatment is dictated by histology. Per current NCCN and ASCO 2025 guidance, the preferred regimens are:

• Non-epithelioid (sarcomatoid + biphasic) — nivolumab + ipilimumab (Nivo+Ipi) is preferred. CheckMate 743 produced a median OS of 18.1 vs. 14.1 months (HR for death 0.74; 96.6% confidence interval [CI] 0.60–0.91; p = 0.002); 3-year follow-up confirmed durable benefit.
• Epithelioid — pemetrexed + cisplatin (Pem+Cis) chemotherapy remains a Category 2A option per institutional formulary citations, with nivolumab + ipilimumab (Nivo+Ipi) and pembrolizumab + pemetrexed + platinum (Pembro+Pem+Plat) as alternatives. EMPHACIS established Pem+Cis as the chemotherapy backbone.

Second-line and beyond

For patients with progression after platinum-based chemotherapy, nivolumab + ipilimumab (Nivo+Ipi) has demonstrated activity in the second-line setting. The INITIATE Phase 2 single-arm trial reported a disease control rate of 68% at 12 weeks and a partial-response rate of 29% in patients with recurrent malignant pleural mesothelioma after prior platinum chemotherapy.

Surgery

Surgery for pleural mesothelioma is reserved for a narrow population: clinical Stage I disease, epithelioid histology, no nodal involvement (N0), adequate cardiopulmonary reserve, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0–1. Sarcomatoid histology is an absolute contraindication to maximal cytoreductive surgery in current NCCN and ASCO 2025 guidance.

When surgery is performed, pleurectomy/decortication (P/D) is preferred over extrapleural pneumonectomy (EPP). The MARS 2 randomized trial (published Lancet Respiratory Medicine, 2024) shifted NCCN and ASCO 2025 toward more conservative surgical patient selection. See Treatment Options — surgery section for the surgical comparison and trial detail.

Tumor treating fields (TTFields)

The NovoTTF-100L System (now Optune Lua) received FDA approval on May 23, 2019, under the Humanitarian Device Exemption (HDE) pathway for use concurrently with pemetrexed and platinum-based chemotherapy in adult patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma. The HDE pathway is reserved for rare conditions and does not require demonstration of effectiveness equivalent to the standard premarket approval (PMA) process.

Pembrolizumab + pemetrexed + platinum (Pembro+Pem+Plat)

The FDA approved pembrolizumab in combination with pemetrexed and platinum chemotherapy for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024. Detailed published efficacy data sit outside the verified-citation pool used for this article; see Treatment_Options for the regulatory context.

Investigational pipeline awareness

Multiple investigational regimens are in active enrollment as of 2026, including mesothelin-targeted chimeric antigen receptor T-cell (CAR-T) therapy (Memorial Sloan Kettering, National Cancer Institute), the tumor-endothelial-marker / Hippo-pathway TEAD inhibitor VT3989 (Vivace Therapeutics), and pegargiminase (ADI-PEG 20) for non-epithelioid disease. See Treatment Options — active clinical trials for the full pipeline table with ClinicalTrials.gov registration numbers.

What is the prognosis for pleural mesothelioma?

Pleural mesothelioma carries one of the poorest prognoses among solid tumors, but prognosis varies substantially by histology, stage at diagnosis, and treatment received. The strongest single prognostic factor is histologic subtype — epithelioid disease consistently outperforms sarcomatoid and biphasic disease in median OS, response to chemotherapy and immunotherapy, and surgical candidacy.

For SEER summary-stage 5-year relative survival statistics — which provide the most current population-based estimate of outcomes — the authoritative public reference is the NCI SEER*Explorer mesothelioma fact sheet. Population-based survival figures lag the era of immunotherapy by several years; the magnitude of OS benefit observed in CheckMate 743 (HR 0.74 across all histologies, with a more pronounced benefit in non-epithelioid disease) is expected to translate into improved registry-level survival as more patients on Nivo+Ipi cycle through the data window.

For peritoneal mesothelioma — anatomically distinct from pleural disease — cytoreductive surgery + hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) produces dramatically better outcomes than systemic therapy alone in eligible patients. Multi-institutional registries report median OS of 38–53 months and 5-year OS of approximately 39–47% in carefully selected patients. See mesothelioma prognosis page for the detailed survival analytics.

How can compensation help cover pleural mesothelioma treatment costs?

Most U.S. pleural mesothelioma patients fund treatment through some combination of insurance and one or more compensation pathways. Because nearly every case has a documented asbestos-exposure history, mesothelioma patients have legal compensation options that are not available to most cancer patients.

• Civil settlements and verdicts — average mesothelioma settlements run $1,000,000–$1,400,000; trial verdicts can be substantially higher. Danziger & De Llano handles mesothelioma claims nationwide; free case evaluation is available at (855) 699-5441.
• Asbestos trust funds — more than 60 trusts hold large reserves to compensate victims of bankrupt asbestos manufacturers. Each trust has its own claim procedure and payment schedule; an attorney experienced in trust filings can identify which trusts a particular work or exposure history qualifies for. See asbestos trust funds page for the program-by-program detail.
• Veterans Affairs (VA) disability compensation — veterans whose mesothelioma is service-connected qualify for VA disability at the 100% rating level, which produces monthly tax-free compensation; survivors may qualify for Dependency and Indemnity Compensation (DIC). See veterans mesothelioma claims for filing procedure.
• Workers' compensation — for occupational exposures, state workers' compensation systems may cover medical expenses and a portion of lost wages, though most occupational mesothelioma cases also have viable third-party product-liability claims that pay substantially more than workers' comp alone.
• Insurance and Medicare — private insurance, Medicare, and Medicaid cover most direct medical costs but rarely cover the full economic impact of treatment, lost wages, and caregiver burden.

For a free, no-obligation review of which of these pathways fit a particular case, contact Danziger & De Llano at (855) 699-5441.

Where can pleural mesothelioma patients find centers of expertise?

Outcomes in pleural mesothelioma — both surgical and systemic — are strongly correlated with center experience. Patients should request referral to a high-volume mesothelioma program for diagnostic confirmation, multidisciplinary treatment planning, and surgical evaluation when applicable.

The full list of NCI-designated cancer centers is available at the National Cancer Institute cancer centers directory; not every NCI-designated center has a high-volume mesothelioma program, so patients should specifically ask whether the center has a dedicated mesothelioma multidisciplinary team.

Related WikiMesothelioma resources:

• Mesothelioma treatment options — full reference
• Mesothelioma treatment costs — detailed breakdown
• Mesothelioma prognosis and survival
• Asbestos exposure overview
• Veterans asbestos exposure pathway
• Veterans mesothelioma claims and VA benefits
• Asbestos trust funds
• Compare mesothelioma settlement outcomes — Danziger & De Llano

Free case evaluation

Danziger & De Llano represents pleural mesothelioma patients and their families nationwide. A case evaluation is free and does not commit a patient or family member to filing a claim. Call (855) 699-5441 24/7 or visit dandell.com to start a confidential review with an attorney who handles mesothelioma cases full-time.